Effects of alfa glucosidase inhibitors (miglitol, voglibose) on efficacy and safety in type 2 diabetic patients with coronary artery disease. - Clinical study on vascular endothelial function improvement effect using coronary flow reserve (CFR) by alfa GI treatment

niversity of Fukui Faculty of Medical Sciences0 个研究点目标入组 40 人开始时间: 2011年6月14日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1)type 1 diabetes mellitus 2)patients who develops asymptomatic hypoglycemia (hypoglycemia unawareness) or severe hypoglycemia repeatedly. 3)patients who have serious liver disease (AST and/or ALT are more than 100 IU/L) 4)patients who have serious kidney disease (Serum Cr is more than 2.0 mg/dL) 5)patients who have serious cardiac disease (patients who have apparent heartfailure or myocardial infarction within 6 months) 6)patients who have serious pancreatic disease 7)patients with cancer 8)patients with serious infection, serious traumatic injury, perioperative period 9)patients with serious diabetic complications including progressed neuropathy and proliferative retinopathy 10)Patients with serious ketosis, diabetic coma, pre-coma 11)patients who have inflammatory bowel disease, ulcer in bowel, ileus and high risk for ilus 12)patinets with chronic bowel diseases which have probability to induce malabsorption syndrome 13)patients who has the disease which is deteriorated with increase of gas in bowel 14)patients who have history of gastrectomy 15)patients with lactose intolerance 16)heavy alcohol drinker (patients who drink more than 480 mL of Japanese Sake, 2L of beer, 180 mL of whisky, 360 mL of wine, or 360 mL of Shochu per day) 17)patients under steroid treatment 18)patients who are pregnant, hope to be pregnant, or are in lactation period 19)patients who are not applicable to this study judged by the medical doctor

发起方

niversity of Fukui Faculty of Medical Sciences